Related Experiment Video
Updated: May 14, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
Liraglutide in type 2 diabetes mellitus
Manash P Baruah1, Tirthankar Chaudhury, Bipin Kumar Sethi
1Excel Center, Guwahati 781007.
Journal of the Indian Medical Association
|January 31, 2013
Summary
Liraglutide effectively manages type 2 diabetes (T2DM) with sustained glycaemic control and weight reduction. This GLP-1 analogue offers greater efficacy than other incretin therapies and is well-tolerated, with mild gastrointestinal events improving over time.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2DM) is a growing global health concern.
- Current therapies aim for glycaemic control, beta-cell function preservation, and weight management.
- Incretin-based therapies represent a significant advancement in T2DM treatment.
Purpose of the Study:
- To review the efficacy and safety of Liraglutide in T2DM management.
- To compare Liraglutide's effectiveness against other incretin-based therapies.
- To assess Liraglutide's role in addressing therapeutic gaps in T2DM.
Main Methods:
- Systematic review of studies evaluating Liraglutide in T2DM.
- Inclusion of Liraglutide as monotherapy and in combination with oral antidiabetic drugs.
- Analysis of glycaemic control, safety, and non-glycaemic outcomes up to 2 years.
Main Results:
- Liraglutide demonstrated superior glycaemic control compared to comparators.
- Sustained glycaemic improvements were observed over a 2-year evaluation period.
- Liraglutide showed significant benefits in weight reduction and systolic blood pressure decrease.
- Mild gastrointestinal adverse events were reported but generally declined with continued therapy.
- A low risk of hypoglycemia was associated with Liraglutide treatment.
Conclusions:
- Liraglutide is a highly effective treatment option for T2DM, offering significant glycaemic and non-glycaemic benefits.
- Its efficacy surpasses that of other incretin-based therapies.
- Liraglutide plays a crucial role in T2DM management by improving beta-cell function, promoting weight loss, and reducing blood pressure.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...